
## **Edwards Pradenas**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9588061/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins. Journal of Infectious Diseases, 2022, 225, 938-946.	1.9	26
2	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Reports Medicine, 2022, 3, 100523.	3.3	18
3	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 278-288.	5.2	61
4	Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities. Age and Ageing, 2022, 51, .	0.7	7
5	Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern. Frontiers in Microbiology, 2022, 13, .	1.5	15
6	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals. Frontiers in Immunology, 2022, 13, 860215.	2.2	6
7	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochemical and Biophysical Research Communications, 2021, 538, 187-191.	1.0	86
8	SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Scientific Reports, 2021, 11, 2608.	1.6	86
9	Stable neutralizing antibody levels 6Âmonths after mild and severe COVID-19 episodes. Med, 2021, 2, 313-320.e4.	2.2	77
10	Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. Viruses, 2021, 13, 1135.	1.5	17
11	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. Open Forum Infectious Diseases, 2021, 8, ofab329.	0.4	7
12	Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro. Journal of Dental Research, 2021, 100, 1265-1272.	2.5	49
13	Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nature Communications, 2021, 12, 4740.	5.8	104
14	First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain. Viruses, 2021, 13, 2526.	1.5	20